Beneficial effects of donor-specific transfusion on renal allograft outcome

Clinical Transplantation

Volumn 25, Issue 2, 2011, Pages 317-324

  Jovičić, Svetlana ^a   Ležaić, Visnja ^a   Simonović, Ruzica ^b   Djukanović, Ljubica ^a  

^a Clinical Centre of Serbia   (Serbia)

^b Blood Transfusion Institute of Serbia   (Serbia)

Author keywords

Donor specific transfusions; Graft function; Kidney graft; Living donor; Outcome

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; METHYLPREDNISOLONE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; DELAYED GRAFT FUNCTION; DRUG DOSE REDUCTION; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; MALE; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; BLOOD DONORS; BLOOD TRANSFUSION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79953327299     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01235.x     Document Type: Article

References (25)

1. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation (part 1). Nephrol Dial Transplant 2000;15 (Suppl. 7):1
2. Opelz G, Vanrenterghem Y, Kirste G. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 1997: 63: 964.
3. Opelz G, Sengar DPS, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973: 5: 253.
4. Bushell A, Karim M, Kingsley CI, Wood KJ. Pretransplant blood transfusion without additional immunotherapy generates Cd25-Cd4- regulatory T cells: a potential explanation for the blood-transfusion effect. Transplantation 2003: 76: 449.
5. Higgins RM, Raymond NT, Krishman NS et al. Acute rejection after renal transplantation is reduced by approximately 50% by prior therapeutic blood transfusions, even in tacrolimus-treated patients. Transplantation 2004: 77: 469.
6. Garcia LF, Arango AM, Rezonezero R et al. Donor specific and random transfusions in HLA haploidentical kidney transplantation. Transplant Proc 1991: 23: 1744.
7. Anderson CB, Brennan D, Keller C et al. Beneficial effects of donor-specific transfusion on long-term renal allograft function. Transplant Proc 1995: 27: 991.
8. Lezaic V, Jovicic S, Simic S et al. Donor-specific transfusion and renal allograft outcome. Nephron 2002: 92: 246.
9. Haisa M, Sakagami K, Matsumoto T et al. Donor-specific transfusion (DST) with intermittent administration of azathioprine induces suppressor T cells and MLR-inhibiting factors without sensitization. Transplant Proc 1989: 21: 1814.
10. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
11. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation (part 2). Nephrol Dial Transplant 2002; 17 (Suppl. 4):1.
12. Satoh S, Sugimura J, Omori S, Seino K, Fujizuka I. Long-term graft survival with or without donor-specific transfusion in cyclosporine era in one-haploidentical living related renal transplant recipients beyond the first year: a 19-year experience. Tohoku J Exp Med 2002: 197: 201.
13. Marti HP, Henschkowski J, Laux G et al. Effect of donor-specific transfusions on the outcome of renal allografts in the cyclosporine era. Transplant Int 2006: 19: 19.
14. Barbari A, Stephan A, Masri MA, Joubran N, Dagher O, Kamel G. Donor specific transfusion in kidney transplantation: effect of different immunosuppressive protocols on graft outcome. Transplant Proc 2001: 33: 2787.
15. Otsuka M, Yuzawa K, Takada Y et al. Long-term graft survival of living-related kidneys after donor-specific transfusions. Transplant Porc 2000: 32: 1741.
16. Kaufman A, De Souza Pontes LF, Queiroz Marques MT, Sampaio JC, De Moraes Sobrino Porto LC, De Moraes Souza ER. Analysis of AHG-PRA and ELISA-PRA in kidney transplant patients with acute rejection episodes. Transpl Immunol 2003: 11: 175.
17. El-Agroudy AE, Ismail AM, El-Chenawy FA, Shehab El-Din AB, Ghoneim MA. Pretransplant mixed lymphocyte culture still has an impact on graft survival. Am J Nephrol 2004: 24: 296.
18. Berg B, Ringden O. Correlation between relative responses in mixed lymphocyte culture, HLA-D and DR typing, and graft survival in renal transplantation. Transplantation 1982: 33: 291.
19. Reinsmoen NL, Matas AJ, Donaldson L, Carter S, and the cooperative clinical trial in transplantation reasearch group Impact of transfusions and acute rejection on posttransplantation donor antigen-specific responses in two study populations. Transplantation 1999: 5: 697.
20. Uchida H, Tanaka H, Kitoch Y et al. Mechanisms of immunomodulation induced by blood transfusion: identification of humoral factors. Transplant Proc 2000: 32: 255.
21. Nimi M, Roelen DL, Witzke O, Van Rood JJ, Claas HJ, Wood KJJ. The importance of H2 haplotype sharing in the induction of specific unresponsiveness by pretransplant blood transfusions. Transplantation 2000: 69: 411.
22. Otsuka M, Yuzawa K, Takada Y et al. Long term results of donor specific blood transfusion with cyclosporine in living related kidney transplantation. Nephron 2001: 88: 144.
23. Fly MW, Burton K, MOhanakumar T et al. Donor-specific transfusions have long term beneficial effects for human renal allografts. Transplantation 1995: 60: 1395.
24. Naumovic R, Djukanovic Lj, Marinkovic J, Lezaic V. Effect of donor age on the outcome of living-related kidney transplantation. Transplant Int 2005: 18: 1266.
25. Kong JM, Jeong JH, Kang JK, Seong IG, Kim BC. Donor-specific transfusion in living related and unrelated donor kidney transplantation: minimal sensitization and excellent graft outcome. Transplant Proc 1995: 27: 1036.